ALDOB and prostate carcinoma: Based on the CellMiner database (Supplementary File 8), the correlation analysis of commonly used therapeutic medicines for prostate cancer verified the therapeutic resistance of docetaxel, and the analysis showed that the medicines were sensitive to the ALDOB gene, especially oxaliplatin and teraplatin (Figure 7F).